Literature DB >> 24950290

FoxO3a nuclear localization and its association with β-catenin and Smads in IFN-α-treated hepatocellular carcinoma cell lines.

María Paula Ceballos1, Juan Pablo Parody, Ariel Darío Quiroga, María Laura Casella, Daniel Eleazar Francés, María Cecilia Larocca, Cristina Ester Carnovale, María de Luján Alvarez, María Cristina Carrillo.   

Abstract

Interferon-α2b (IFN-α2b) reduces proliferation and increases apoptosis in hepatocellular carcinoma cells by decreasing β-catenin/TCF4/Smads interaction. Forkhead box O-class 3a (FoxO3a) participates in proliferation and apoptosis and interacts with β-catenin and Smads. FoxO3a is inhibited by Akt, IκB kinase β (IKKβ), and extracellular-signal-regulated kinase (Erk), which promote FoxO3a sequestration in the cytosol, and accumulates in the nucleus upon phosphorylation by c-Jun N-terminal kinase (JNK) and p38 mitogen-activated kinase (p38 MAPK). We analyzed FoxO3a subcellular localization, the participating kinases, FoxO3a/β-catenin/Smads association, and FoxO3a target gene expression in IFN-α2b-stimulated HepG2/C3A and Huh7 cells. Total FoxO3a and Akt-phosphorylated FoxO3a levels decreased in the cytosol, whereas total FoxO3a levels increased in the nucleus upon IFN-α2b stimulus. IFN-α2b reduced Akt, IKKβ, and Erk activation, and increased JNK and p38 MAPK activation. p38 MAPK inhibition blocked IFN-α2b-induced FoxO3a nuclear localization. IFN-α2b enhanced FoxO3a association with β-catenin and Smad2/3/7. Two-step coimmunoprecipitation experiments suggest that these proteins coexist in the same complex. The expression of several FoxO3a target genes increased with IFN-α2b. FoxO3a knockdown prevented the induction of these genes, suggesting that FoxO3a acts as mediator of IFN-α2b action. Results suggest a β-catenin/Smads switch from TCF4 to FoxO3a. Such events would contribute to the IFN-α2b-mediated effects on cellular proliferation and apoptosis. These results demonstrate new mechanisms for IFN-α action, showing the importance of its application in antitumorigenic therapies.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24950290      PMCID: PMC4217017          DOI: 10.1089/jir.2013.0124

Source DB:  PubMed          Journal:  J Interferon Cytokine Res        ISSN: 1079-9907            Impact factor:   2.607


  56 in total

1.  Inhibition of CDK2, CDK4 and cyclin E and increased expression of p27Kip1 during treatment with interferon-alpha in carcinoid tumor cells.

Authors:  Y Zhou; S Wang; A Gobl; K Oberg
Journal:  J Biol Regul Homeost Agents       Date:  1999 Oct-Dec       Impact factor: 1.711

2.  Interferon-alpha induces TRAIL expression and cell death via an IRF-1-dependent mechanism in human bladder cancer cells.

Authors:  Angela Papageorgiou; Colin P N Dinney; David J McConkey
Journal:  Cancer Biol Ther       Date:  2007-03-01       Impact factor: 4.742

3.  Interaction of FOXO with beta-catenin inhibits beta-catenin/T cell factor activity.

Authors:  Diana Hoogeboom; Marieke A G Essers; Paulien E Polderman; Erik Voets; Lydia M M Smits; Boudewijn M Th Burgering
Journal:  J Biol Chem       Date:  2008-02-04       Impact factor: 5.157

Review 4.  FOXO transcription factors at the interface between longevity and tumor suppression.

Authors:  Eric L Greer; Anne Brunet
Journal:  Oncogene       Date:  2005-11-14       Impact factor: 9.867

5.  Reciprocal interference between insulin and interferon-alpha signaling in hepatic cells: a vicious circle of clinical significance?

Authors:  Lisa Franceschini; Stefano Realdon; Moira Marcolongo; Silvia Mirandola; Gladis Bortoletto; Alfredo Alberti
Journal:  Hepatology       Date:  2011-06-23       Impact factor: 17.425

6.  p27, a novel inhibitor of G1 cyclin-Cdk protein kinase activity, is related to p21.

Authors:  H Toyoshima; T Hunter
Journal:  Cell       Date:  1994-07-15       Impact factor: 41.582

7.  Study of the effects of interferon a on several human hepatoma cell lines: analysis of the signalling pathway of the cytokine and of its effects on apoptosis and cell proliferation.

Authors:  A Legrand; N Vadrot; B Lardeux; A F Bringuier; R Guillot; G Feldmann
Journal:  Liver Int       Date:  2004-04       Impact factor: 5.828

8.  Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase.

Authors:  Anne Brunet; Lora B Sweeney; J Fitzhugh Sturgill; Katrin F Chua; Paul L Greer; Yingxi Lin; Hien Tran; Sarah E Ross; Raul Mostoslavsky; Haim Y Cohen; Linda S Hu; Hwei-Ling Cheng; Mark P Jedrychowski; Steven P Gygi; David A Sinclair; Frederick W Alt; Michael E Greenberg
Journal:  Science       Date:  2004-02-19       Impact factor: 47.728

9.  MDM2 acts downstream of p53 as an E3 ligase to promote FOXO ubiquitination and degradation.

Authors:  Wei Fu; Qiuping Ma; Lei Chen; Pengfei Li; Mu Zhang; Sivapriya Ramamoorthy; Zafar Nawaz; Tsukasa Shimojima; Hengbin Wang; Yonghua Yang; Zheng Shen; Yingtao Zhang; Xiaohong Zhang; Santo V Nicosia; Yanping Zhang; Jack W Pledger; Jiandong Chen; Wenlong Bai
Journal:  J Biol Chem       Date:  2009-03-25       Impact factor: 5.157

10.  p38 MAP kinase mediates arsenite-induced apoptosis through FOXO3a activation and induction of Bim transcription.

Authors:  Beibei Cai; Zhengui Xia
Journal:  Apoptosis       Date:  2008-06       Impact factor: 4.677

View more
  3 in total

1.  Salinomycin decreases doxorubicin resistance in hepatocellular carcinoma cells by inhibiting the β-catenin/TCF complex association via FOXO3a activation.

Authors:  Yue Zhou; Chao Liang; Fei Xue; Wei Chen; Xiao Zhi; Xinhua Feng; Xueli Bai; Tingbo Liang
Journal:  Oncotarget       Date:  2015-04-30

2.  KPT-330, a potent and selective exportin-1 (XPO-1) inhibitor, shows antitumor effects modulating the expression of cyclin D1 and survivin [corrected] in prostate cancer models.

Authors:  Giovanni Luca Gravina; Andrea Mancini; Patrizia Sanita; Flora Vitale; Francesco Marampon; Luca Ventura; Yosef Landesman; Dilara McCauley; Michael Kauffman; Sharon Shacham; Claudio Festuccia
Journal:  BMC Cancer       Date:  2015-12-01       Impact factor: 4.430

3.  TTC36 inactivation induce malignant properties via Wnt-β-catenin pathway in gastric carcinoma.

Authors:  Lei Song; Xiaonong Guo; Fei Zhao; Wei Wang; Zhifang Zhao; Long Jin; Chengli Wu; Jibin Yao; Zhongren Ma
Journal:  J Cancer       Date:  2021-03-05       Impact factor: 4.207

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.